Scientific paper - Original scientific paper
Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)
Cancer Biomarkers, 30 (2021), 1; 95-104. https://doi.org/10.3233/CBM-201497


Cite this document

Sirotković Skerlev, M., Plavetić, N. D., Sedlić, F., Kuna, S. K., Vrbanec, D., Belev, B. ... Kulić, A. (2021). Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomarkers, 30. (1), 95-104. doi: 10.3233/CBM-201497

Sirotković Skerlev, Maja, et al. "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)." Cancer Biomarkers, vol. 30, no. 1, 2021, pp. 95-104. https://doi.org/10.3233/CBM-201497

Sirotković Skerlev, Maja, Natalija Dedić Plavetić, Filip Sedlić, Sanja Kusačić Kuna, Damir Vrbanec, Borislav Belev, Stjepko Pleština, Zdenko Kovač and Ana Kulić. "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)." Cancer Biomarkers 30, no. 1 (2021): 95-104. https://doi.org/10.3233/CBM-201497

Sirotković Skerlev, M., et al. (2021) 'Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)', Cancer Biomarkers, 30(1), pp. 95-104. doi: 10.3233/CBM-201497

Sirotković Skerlev M, Plavetić ND, Sedlić F, Kuna SK, Vrbanec D, Belev B, and sur.. Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomarkers [Internet]. 2021 [cited 2021 November 27];30(1):95-104. doi: 10.3233/CBM-201497

M. Sirotković Skerlev, et al., "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)", Cancer Biomarkers, vol. 30, no. 1, pp. 95-104, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:834430. [Accessed: 27 November 2021]

Please login to the repository to save this object to your list.